A pharmaceutical brand should evaluate AI visibility services on methodology fit, not feature counts or price. The four methodology criteria that matter are platform coverage breadth, pharma-specific buyer question design, competitive benchmarking, and impact-ranked findings. This framework is grounded in AEO Dose's own audit methodology, disclosed below as a worked example, and written so you can apply it to any vendor you are considering.
What you'll learn
- Why a feature count or a price tag tells you almost nothing about fit
- What separates pharma AI visibility work from general AEO practice
- How many AI assistants a service should actually test, and why
- Why the design of buyer questions matters more than their count
- What competitive benchmarking looks like inside a real audit
- How to tell a useful findings report from a weak one
- When a Free Check is enough and when you need a Full Audit
- The exact questions to put to any vendor this week
Why comparing AI visibility services for pharma is not a feature count exercise
Comparing AI visibility services by counting features or sorting by price will mislead you, because the thing you are actually buying is a method for finding out how AI assistants answer your buyers. Two vendors can both claim to "test ChatGPT and track citations" and deliver completely different value depending on how they design the test. One produces a ranked list of fixable gaps. The other produces a screenshot folder.
The decision problem for an API manufacturer, a CDMO, or an excipient supplier is not "which service has the longest feature list." It is "which service will tell me, in terms I can act on, why a buyer asking an AI assistant for a supplier does not get my name back." Price is a downstream consideration once methodology fit is established. The reasons price alone fails as a comparison signal are covered in more depth in the Understanding Pricing for AI Visibility Services cluster, which is worth reading before you let a quote anchor your decision.
What makes pharma AI visibility different from general AEO
Pharma AI visibility differs from general AEO because the buyer questions, the entity relationships, and the evidence a buyer needs are domain-specific in ways a generalist vendor will not anticipate. A buyer evaluating a solid dose CDMO asks about regulatory inspection history, dosage form capability, and capacity, not about generic "services" or "products." If a vendor does not know what a buyer means when they ask an AI assistant to compare excipient suppliers by functionality, the questions they construct will be too shallow to surface a real gap.
If you need a grounding in how AI answer optimization differs from traditional search before going further, the Understanding AI Visibility and AEO cluster covers the foundational concepts this article assumes. My own background is twelve years of pharma ERP implementation and computer system validation, and the recurring lesson is the same: domain context is not a nice-to-have overlay on a generic method. Most SEO agencies have not retooled for AEO at all, and the ones that bolt an AEO add-on onto an SEO practice tend to carry over keyword-era assumptions that do not map to how AI assistants synthesize answers.
Criterion one: platform coverage breadth across the five major AI assistants
A service should test across the five AI assistants your buyers actually use: ChatGPT, Gemini, Perplexity, Claude, and Grok. Coverage breadth matters because these systems do not draw on the same sources or synthesize answers the same way. A brand can be cited confidently by one assistant and absent from another, and a single-platform test hides that split entirely.
As a worked example, AEO Dose's Free Check covers two platforms and the Full Audit covers all five. The point of naming that structure is not to sell it, but to give you a concrete yardstick: ask any vendor exactly which assistants they query and whether their report separates results by platform. A service that reports a single blended "AI visibility score" without per-platform breakdown is averaging away information you need to prioritize work.
Criterion two: how buyer questions are designed, not just how many are tested
Question design matters more than question count because a small set of questions that mirror real buyer intent reveals more than a large set of generic prompts. The relevant test is not "does the AI mention my brand," it is "when a buyer in my category asks the question they would actually ask, does my brand appear, and in what light."
AEO Dose's Free Check runs ten real buyer questions, and the Full Audit organizes questions across five buyer journey themes: discovery, evaluation, product and capability, commercial, and support. For a nutraceutical brand or an oral care manufacturer, a discovery question and a commercial question surface different gaps, and collapsing them into one bucket loses that signal. The way a question is framed for a CDMO versus an excipient supplier changes what a good answer even looks like, which is why industry grounding is not optional. The Industry-Specific Visibility Challenges cluster works through how different pharma segments appear, or fail to appear, in these answers. When you review a vendor's sample questions, read them as a buyer in your own category and ask whether you would actually phrase a query that way.
Criterion three: competitive benchmarking methodology
Competitive benchmarking inside an audit means testing the same buyer questions and recording which other suppliers the AI assistant names, so you can see your position relative to the set of answers a buyer receives. Without benchmarking, you learn whether you were mentioned, but not whether competitors were named ahead of you for the same question. That second fact is what tells you how much ground there is to make up.
AEO Dose's Full Audit includes competitive benchmarking across the five buyer journey themes. Note the constraint this article operates under and the one a credible vendor should share: benchmarking describes who appears in answers, not a promise about where you will rank after the work. In the absence of competitive benchmarking, a report can show you absent from an answer while leaving you blind to whether the category is wide open or already crowded. Ask any vendor how they handle the competitive dimension and whether their output names the comparison set or just scores you in isolation.
Criterion four: how findings are prioritized and delivered
Findings should be prioritized by expected impact and delivered as specific actions, not as a raw inventory of everything observed. A weak findings report lists problems. A useful one tells you which gap to close first, why it matters for your buyers, and what fixing it involves. The difference is the difference between a document you file and a document you work from.
For a pharma operator with limited internal bandwidth, an unranked observation list is close to useless, because the cost of deciding what to do first lands back on you. When you evaluate a vendor's sample report, look for whether findings are ordered by impact and tied to a concrete change, not just flagged. How findings feed an ongoing cycle rather than a one-off document is covered in the Audit and Optimization Process cluster, which is worth reading alongside any vendor's sample deliverable.
Free Check versus Full Audit: when each is the right starting point
A Free Check is the right starting point when you want to validate a vendor's method at low commitment, and a Full Audit is right when you are ready to act on a complete, benchmarked picture. The Free Check exists precisely to let you test the question design and output quality before you spend anything, which is also an honest way to compare vendors who offer one.
AEO Dose structures this as a Free Check covering two platforms and ten buyer questions, and a Full Audit covering all five platforms with competitive benchmarking across the five buyer journey themes. Use a free entry point from any vendor to run the criteria above as a live test: did the sample questions read like your buyers, was the output per-platform, was it actionable. The practical mechanics of each tier are detailed in the Audit and Optimization Process cluster.
Put the methodology to the testRun the six criteria above against any vendor's free entry point, including this one. No payment required for the baseline report.
Get Your Free AI Visibility CheckSix questions to ask any AI visibility vendor before committing
Put these six questions to any vendor you are considering this week, and judge the answers against the criteria above rather than against a price sheet:
- Which of the five AI assistants (ChatGPT, Gemini, Perplexity, Claude, Grok) do you test, and does your report break results out per platform?
- Can I see the actual buyer questions you would run for a company in my pharma segment, and who writes them?
- Does your audit record which competing suppliers the AI names for the same questions, or only whether I appear?
- Are findings ranked by impact and tied to specific actions, or delivered as an observation list?
- What does your free or entry-level check include, and what changes in the full engagement?
- Can you point me to references or reviews I can verify independently?
On that last point, how to validate a vendor's claims through references is covered in the Checking Reviews for AI Services cluster. A vendor who answers all six plainly is showing you their method. One who redirects to a feature list or a discount is showing you something else. A low-commitment way to run this test on any vendor, including this one, is to put a free check through the same six questions: Get Your Free AI Visibility Check.



